Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Im false

קמהדע בע"מ	2 380
KAMADA LTD
Corporation no: 511524605	12585

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	08/09/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-099237	Time of broadcast: 13:53 13:53

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)

ea126541-6k_kamadaltdEDGAR1_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: TASE	Date of revision of form structure: 04/08/2020
Address: Holtzman 2 4081 , Rehovot 7670402   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: liorf@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: Fhima Lior Position of Signatory in the reporting corporation: Director of Finance Name of Employer Company:
Address: Haim holtzman 2 , Rehovot 7670402 Telephone: 08-9913168 Facsimile: 08-9912083 E-mail: liorf@kamada.com 2